Production of anti-breast cancer monoclonal antibodies using a glutathione-S-transferase-MUC1 bacterial fusion protein V. Apostolopoulos, P.-X. Xing 48 /53 breast cancers and both also reacted with a range of other human epithelial carcinomas. In addition VAI gave weak reactions with normal breast tissues whereas VA2 was non-reactive and could be a relatively tumour specific antibody for breast cancer. The antibodies were also tested by ELISA-VAI reacted weakly with glycosylated HMFG but strongly with deglycosylated HMFG, whereas VA2 reacted strongly with both forms of HMFG. The reactivities of the two Mabs with synthetic peptides of the MUCI tandem repeat were used to map the epitopes recognised by VAI (amino acids RPAPGS) and VA2 (amino acids DTRPA). The use of fusion proteins provides another means of immunisation to produce anti-tumour antibodies.
Mucins are heavily glycosylated glycoproteins (> 200 Kd) which are produced by many epithelial cells and tumours (Gendler et al., 1988) . Mucins found on cancer cells are different in some respects to those present on normal epithelial cells, in that some mucins have a deficiency in their carbohydrate coat which leaves the protein core exposed (Harisch et al., 1989) . Monoclonal antibodies (Mabs) reacting with the mucin core proteins may therefore show a different reactivity with normal and malignant tissues. This raises the possibility that some epitopes of mucins may act as markers for the malignant state and/or as targets against which therapeutic Mabs could be directed. The cDNA sequence of the protein core of the mammary mucin, MUCI, has been cloned and found to consist of unique amino and carboxyl sequences separated by a highly repetitive central portion containing 40-80 tandemly arranged copies of a 20 amino acid motif (APDTRPAPGSTAPPAHGVTS) (Marjolijn et al., 1990) . As the number of repeats expressed by any individual is polymorphic, this region is referred to as VNTR (variable number tandem repeats), but there is no association between the number of repeats and susceptibility to malignancy (Crocker & Price, 1987) . Mabs have been raised against naturally occurring mucin in human milk fat globule protein (HMFG) and against synthetic peptides representing portions of the repetitive region (Xing et al., 1989) and some of these antibodies have been found to be useful markers of progression of malignant disease and in imaging tumour deposits (Xing et al., 1989 (Xing et al., 1992 (Siddiqui et al., 1988) was subcloned into the bacterial expression vector pGEX-3X, in the correct reading frame and orientation (Smith & Johnson, 1988) . Fusion protein, consisting of glutathione-S-transferase (GST) and MUCI VNTR, was induced with 0.1 mM IPTG (Smith & Johnson, 1988) . Cells were collected by centrifugation, washed and lysed by sonication in buffer containing 1% (v/v) Triton X-100. Supernatant containing the soluble fusion protein was mixed with glutathione-agarose beads (sulphurlinked) (Sigma, St. Louis, USA) and collected by centrifugation. The fusion protein was eluted with buffer containing 5 mM reduced glutathione, dialysed against phosphate buffered saline and analysed by SDS-PAGE.
Preparation ofpeptides and HMFG Peptides (Table I) were synthesised using an Applied Biosystems Model 430A automated peptide synthesiser (Hodges & Merrifield, 1975; Kent & Hood, 1984) . HMFG and deglycosylated HMFG were prepared as previously described (Xing et al., 1989 (Stacker et al., 1985) and the reactions graded ac- cording to the percentage of cells stained: 0% (-), <25% (1+), 25-50% (2+), 50-75% (3 + ),>75% (4+) and the intensity of staining: negative (-), weak (1 + ), moderate (2 + ), strong (3 + ), very strong (4 + ). The solid phase and the inhibition (liquid phase) ELISA tests were performed as described (Xing et al., 1989; Xing et al., 1991) . For the direct test, 20 igmlml of peptides and 10ligmlm' of HMFG and deglycosylated HMFG were coated in the wells of a microtitre plate. Non specific binding was blocked and the antibody reacted for 2 h. For the inhibition studies C-p13-32 pre-coated plates (20 pg ml-1) were used to test the peptides, which at increasing concentrations (3.6 x 10-5-0.08 mM) were mixed with the antibodies and left on the plates for 2 h.
Epitope mapping using the pepscan method Peptides corresponding to the MUC1 sequence were synthesised on polyethylene pins and consisted of twenty overlapping 6-mer peptides e.g. PDTRPA, DTRPAP, TRPAPG
APDTRP. The Mabs were tested for binding to the peptides on pins using the ELISA method (Xing et al., 1991) .
Results

Production of Mabs detecting a GST-MUCI fusion protein
A bacterial fusion protein consisting of GST (26 Kd) and five repeats of the MUC1 VNTR 20-mer peptide was induced in E. coli, purified and used to raise Mabs. Hybridomas were selected on the basis of reactivity with the MUC1 fusion protein, lack of reactivity with an irrelevant synthetic peptide (T4NI) and GST (Table I) , and a reaction on formalin fixed breast cancer tissues detected by the immunoperoxidase technique. Two hybridomas, VA1 and VA2 were selected for further study on the basis of the selection criteria.
Reaction of Mabs with synthetic peptides, HMFG and the fusion protein Each antibody was tested on natural and deglycosylated HMFG, the fusion protein and on a number of peptides whose sequence was based on that of the MUC1 VNTR sequence (Table I ). In addition to the immunising fusion protein (VNTR-GST), VAI reacted strongly with C-pl3-32 (a dimeric form of p13-32, composed of disulphide linked monomers) and with deglycosylated HMFG but weakly with the p13-32 monomer peptide and with the fully glycosylated HMFG. The reactivity with the dimer peptide (C-pl3-32) but not with p13-32 or other monomeric peptides (Table I) was of interest and indicated that the antibodies may be more reactive when a secondary structure is allowed to form. We found however that small peptides synthesised on pins were reactive (see below). To further study the reactions, the peptides were used in inhibition studies (Figure la, b) and the differences noted in direct studies were not observed. For these studies, peptides in solution were used to inhibit the reaction of VAI (Figure la) with C-p13-32 on the plate. The peptides C-pl3-32, p13-32, pl-15, pl-24 and p5-20 all inhibited; in particular, C-p13-32 and p13-32 on a molar basis, gave similar inhibition. HMFG also gave some inhibition, although virtually no reaction was noted when HMFG was coated on the plate (Table I ). The reactions of VA2 were similar to VAI but with some notable differences. In addition to the immunisating fusion protein, VA2 reacted with both forms of HMFG. The peptides C-pl3-32, p13-32, pl-15, and pl-24 all inhibited in the inhibition assay (Figure lb) although in the solid phase ELISA only C-p13-32 was reactive (Table I) .
Reaction of Mabs with human tissue
The reactivities of the two antibodies VAI and VA2 with various tumours are shown in Table II and Table IV . Using the immunoperoxidase staining technique Mab VAI reacted with 46/53 (87%) breast cancers and VA2 with 48/53 (91%) (Figure 2 ). VAI and VA2 were clearly not breast cancer specific as they reacted with other cancers (Tables II and IV) . VAl gave weak reactions with formalin fixed normal breast epithelial cells in acini and ducts, but a stronger reaction on fresh breast tissues (Figure 3a) , whereas VA2 showed no such reaction on all formalin fixed tissues and a weak reaction with fresh normal breasts (Figure 3b ). Both Mabs gave additional weak reactions (luminal, cell surface, secretion, cytoplasmic) with other normal tissues (Table III and Table V) . Both VAl and VA2 reacted strongly with normal colon tissues (all cells within the gland were positive). MUC1 protein is not thought to be expressed by normal colon but we note that normal colon does indeed express MUC1 ( Figure  4 ). Likewise with normal ovary both antibodies reacted with formalin fixed tissues. In general, the staining was weaker on normal tissues than on cancer tissues and stronger on fresh tissue than on formalin fixed tissue. Comparing the two Mabs with Mab BC2 (an anti-MUCI antibody produced using whole mucin HMFG as the immunogen and which reacted with the amino acids APDTR) some differences were noted. The staining intensity of BC2 on both normal kidney and carcinoma of the kidney was intense, in contrast to VAl and VA2 where much weaker reactions were observed. In addition the staining intensity of VAl and VA2 in some breast carcinomas was more intense than that of BC2. Also the staining pattern of BC2 on colon carcinoma (formalin fixed) was different to that of VA1 and VA2 as BC2 showed a luminal staining pattern and stained the secretions, whereas VA1 and VA2 showed only a weak cytoplasmic staining only (data not shown). Thus, the staining properties of the anti- Epitopes detected by VAI and VA2 To define the precise epitopes detected by VAI and VA2, the 'pepscan' method was used. In this method overlapping peptides were examined and the peptide RPAPGS showed a strong reaction with VA1 and the peptides TRPAPG, PAPGST and APGSTA gave a weaker reaction. APG is common and is a partial epitope whereas RPAPGS the full epitope ( Figure 5a ). For VA2 the two peptides DTRPAP and PDTRPA showed strong reactivity and the common amino acids in the epitope are DTRPA ( Figure Sb Mab NCRC-l 1 (Price et al., 1990) recognises the epitope RPA. This epitope is in the hydrophilic turn region of the peptide and suggests that the peptide core is exterior of the glycoprotein where the antibody binds. The amino acids PDTRPAP are exposed in cancer mucins, and indeed VAI and VA2 have reactive epitopes within this region. It was also shown that in the 20 amino acid repeat there is no potential for P sheet or a helix formation (Price et al., 1990) .
High field NMR studies were taken from 11 amino acid fragment of the sequence, and revealing elements of secondary structure to be present . A type 1 p turn from D(2)-R(4) was found which extends by P(3) being in the trans form. The turn region extends into the epitopes known for Mabs such as C595 and NCR-Il (Price et al., 1990) basis of the reactivity of the SM3 antibody (made to deglycosylated HMFG) (Burchell et al., 1987) that there is altered or defective glycosylation in malignancy, so antibodies to MUCI core proteins react weakly with normal tissue and HMFG, but more strongly on deglycosylated HMFG and cancer cells, i.e. VAI pattern. The reactivity of VA2 is similar other than for the stronger reaction on whole HMFG. The reason for this is not clear, possibly the DTRPA epitope is exposed in HMFG than the epitope RPAPGS; it is possible that threonine (T) in DTRPA is not glycosylated, clearly making this epitope more accessible. Other DTR reactive Abs are SM3 and HMFG (Burchell et al., 1989) and SM3 in particular does not react with HMFG but does so with deglycosylated HMFG. Both antibodies showed no reaction with synthetic peptides pl-15, pl-24, and p13-32 in a solid phase ELISA (Table I) even though they contain the epitope recognised by the antibodies. However both antibodies could react with the peptides in liquid phase (in the inhibition studies). It is likely that the peptides in a solid phase lose conformation as they attach to the plate, and the antibodies are unable to see their corresponding determinants. Thus, although the predominant reaction is with the primary sequence of the peptide, some conformational alteration occurs in solution or when the peptide is attached at one end, as with the pins, permitting stronger reaction with the antibody.
Fusion proteins have recently been used to test antibodies, e.g. MUCI for HMFG-1 and HMFG-2 and for anti-CEA antibodies to map the domain reactivity (Burchell et al., 1987; Hass et al., 1991) . We now show that fusion proteins can also be used to produce antibodies. Are these of any advantage over HMFG, tumour extracts or synthetic peptide -it remains to be seen in various diagnostic and therapeutic tests. However the differential reactivity on HMFG and deglycosylated HMFG, on C-pl3-32 vs p13-32 and on tumour and normal tissues (i.e. VA2) indicate that these antibodies may be the most specific made thus far. The Mab SM3 (Burchell et al., 1987) which recognises an epitope exposed in the mucin as processed by the tumour cells and not exposed on normal mucin, gave weak reactions with normal breast and other normal tissues. VA2 reacted with normal tissues and reacted weakly with only fresh normal breast, indicating that it may be a useful diagnostic or therapeutic agent for breast cancer.
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